TGM4

Summary

TGM4 (transglutaminase 4, HGNC:11780) is a protein-coding gene on chromosome 3p21.31, encoding Protein-glutamine gamma-glutamyltransferase 4 (P49221). Associated with the mammalian reproductive process.

Predicted to enable protein-glutamine gamma-glutamyltransferase activity. Predicted to act upstream of or within mating plug formation. Located in Golgi apparatus and collagen-containing extracellular matrix.

Source: NCBI Gene 7047 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 109 total — 1 likely-pathogenic
• MANE Select transcript: NM_003241

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11780
Approved symbol	TGM4
Name	transglutaminase 4
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	TGP
Ensembl gene	ENSG00000163810
Ensembl biotype	protein_coding
OMIM	600585
Entrez	7047

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 3 retained_intron, 2 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000296125, ENST00000422219, ENST00000459830, ENST00000471637, ENST00000490928, ENST00000495844, ENST00000705784

RefSeq mRNA: 1 — MANE Select: NM_003241 NM_003241

CCDS: CCDS2723

Canonical transcript exons

ENST00000296125 — 14 exons

Exon	Start	End
ENSE00001078512	44887689	44887795
ENSE00001614094	44901793	44901931
ENSE00001619821	44903884	44903987
ENSE00001648274	44910958	44911127
ENSE00001655997	44906949	44907200
ENSE00001699086	44901524	44901698
ENSE00001717266	44910090	44910368
ENSE00001755070	44911270	44911406
ENSE00001893162	44874608	44874697
ENSE00003476227	44893577	44893695
ENSE00003506971	44890603	44890732
ENSE00003547487	44885325	44885498
ENSE00003577279	44896709	44896816
ENSE00003994158	44913584	44914990

Expression profiles

Bgee: expression breadth broad, 100 present calls, max score 84.94.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0536 / max 41.9902, expressed in 6 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36351	0.0536	6

Top tissues by expression

123 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.94	gold quality
prostate gland	UBERON:0002367	81.06	gold quality
bone marrow	UBERON:0002371	60.69	gold quality
bone marrow cell	CL:0002092	59.67	gold quality
monocyte	CL:0000576	58.37	gold quality
leukocyte	CL:0000738	57.94	gold quality
vermiform appendix	UBERON:0001154	56.97	gold quality
granulocyte	CL:0000094	56.06	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	53.73	gold quality
right testis	UBERON:0004534	52.96	gold quality
testis	UBERON:0000473	51.99	gold quality
left testis	UBERON:0004533	51.79	gold quality
right coronary artery	UBERON:0001625	49.82	gold quality
right adrenal gland	UBERON:0001233	49.37	gold quality
adrenal gland	UBERON:0002369	48.08	gold quality
left adrenal gland cortex	UBERON:0035825	47.94	gold quality
left adrenal gland	UBERON:0001234	47.30	gold quality
endocervix	UBERON:0000458	46.12	gold quality
gastrocnemius	UBERON:0001388	46.06	gold quality
skeletal muscle tissue	UBERON:0001134	45.85	silver quality
tonsil	UBERON:0002372	45.22	gold quality
blood	UBERON:0000178	45.19	gold quality
ectocervix	UBERON:0012249	45.14	gold quality
skeletal muscle organ	UBERON:0014892	44.95	gold quality
muscle of leg	UBERON:0001383	44.92	gold quality
skin of abdomen	UBERON:0001416	44.85	gold quality
uterine cervix	UBERON:0000002	43.95	gold quality
muscle tissue	UBERON:0002385	43.69	silver quality
zone of skin	UBERON:0000014	43.60	gold quality
ventricular zone	UBERON:0003053	43.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.16

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RARG, SP1, SP3

miRNA regulators (miRDB)

46 targeting TGM4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3681-5P	99.82	66.88	387
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-18A-3P	99.56	65.68	1092
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4728-3P	99.47	68.94	981
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-1304-5P	98.90	68.58	1054
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-5006-5P	98.79	66.92	1246
HSA-MIR-4297	98.77	66.95	2013
HSA-MIR-4725-5P	98.67	65.42	628
HSA-MIR-504-5P	98.67	65.40	631
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-518C-5P	98.53	69.20	1640
HSA-MIR-4266	98.53	67.29	1035
HSA-MIR-628-5P	98.36	67.74	844
HSA-MIR-4733-3P	98.35	65.20	994
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-4457	98.09	67.12	1274

Literature-anchored findings (GeneRIF, showing 12)

• transglutaminase 4 has a relatively wide profile of expression in human cancer cell lines (PMID:17552366)
• TGase-4 plays a pivotal role in the interaction between endothelial cells and prostate cancer cells, an action which is independent of the ROCK pathway. (PMID:18983858)
• The expression status of human transglutaminase 4 in benign prostate hyperplasia (BPH) and prostate cancer was analyzed. (PMID:20177144)
• TGase-4 expression is intrinsically linked to the activation of RON in prostate cancer cells and that this autoactivation of RON contributes to the increased cell motility in TGase-4 expressing cells. (PMID:20596668)
• The presence of TGase-4 has a biological impact on a prostate cancer cell’s response to MDA-7. (PMID:21524313)
• CDKN2A, GATA3, CREBBP, ITGA2, NBL1 and TGM4 were down-regulated in the prostate carcinoma glands compared to the corresponding normal glands (PMID:21743959)
• Evidence that the retinoic acid receptor gamma plays a major role in the regulation of the hTGP gene and that presence of the androgen receptor, but not its transcriptional transactivation activity, is critical for hTGP transcription. (PMID:22362749)
• indicated that transglutaminase 4 may serve as a potential predictor of biochemical recurrence of prostate cancer (PMID:23974364)
• TGM4 is a prostatic secretory molecule with critical role in male reproduction. (PMID:26084804)
• TGM4 is elevated in the seminal plasma of prostate cancer patients. (PMID:31249104)
• Biochemical Characterisation of Human Transglutaminase 4. (PMID:34830327)
• Transglutaminase-4 (Prostate Transglutaminase), a Potential Biological Factor and Clinical Indicator for the Diagnosis and Prognosis of Prostate Cancer. (PMID:36585193)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tgm4	ENSMUSG00000025787
rattus_norvegicus	Tgm4	ENSRNOG00000004320
drosophila_melanogaster	Tg	FBGN0031975

Paralogs (8): TGM1 (ENSG00000092295), TGM5 (ENSG00000104055), F13A1 (ENSG00000124491), TGM3 (ENSG00000125780), TGM7 (ENSG00000159495), EPB42 (ENSG00000166947), TGM6 (ENSG00000166948), TGM2 (ENSG00000198959)

Protein

Protein identifiers

Protein-glutamine gamma-glutamyltransferase 4 — P49221 (reviewed: P49221)

Alternative names: Fibrinoligase, Prostate transglutaminase, Prostate-specific transglutaminase, Transglutaminase P, Transglutaminase-4

All UniProt accessions (3): A0A994J576, P49221, F8WCU8

UniProt curated annotations — full annotation on UniProt →

Function. Associated with the mammalian reproductive process. Catalyzes the cross-linking of proteins and the conjugation of polyamines to specific proteins in the seminal tract.

Subunit / interactions. Homodimer.

Tissue specificity. Prostate.

Cofactor. Binds 1 Ca(2+) ion per subunit.

Similarity. Belongs to the transglutaminase superfamily. Transglutaminase family.

RefSeq proteins (1): NP_003232* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001102	Transglutaminase_N	Domain
IPR002931	Transglutaminase-like	Domain
IPR008958	Transglutaminase_C	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR013808	Transglutaminase_AS	Active_site
IPR014756	Ig_E-set	Homologous_superfamily
IPR023608	Transglutaminase_animal	Family
IPR036238	Transglutaminase_C_sf	Homologous_superfamily
IPR036985	Transglutaminase-like_sf	Homologous_superfamily
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily
IPR050779	Transglutaminase	Family

Pfam: PF00868, PF00927, PF01841

Enzyme classification (BRENDA):

• EC 2.3.2.13 — protein-glutamine gamma-glutamyltransferase (BRENDA: 68 organisms, 476 substrates, 772 inhibitors, 122 Km, 49 kcat entries)

Substrate kinetics (BRENDA)

60 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PUTRESCINE	0.035–9.63	13
L-LYSINE	2.9–15.8	6
N-CBZ-GLN-GLY	12.83–59.5	5
HYDROXYLAMINE	1.37–61.9	4
NALPHA-BENZYLOXYCARBONYL-L-GLN-GLY	11.2–30	4
CASEIN	0.006–0.012	3
CBZ-GLN-GLY	0.0169–5.9	3
CBZ-GLN-GLY-OH	3.53–8.55	3
METHYLAMINE	0.024–0.061	3
MONODANSYLCADAVERINE	0.01–0.034	3
N-CARBOXYBENZOYL-L-GLUTAMINYL-GLYCINE	0.0547–69.4	3
PENTYLAMINE	0.0029–0.0203	3
Z-GLN-GLY	1.8–11.6	3
ACETYL-ALPHAS1-CASEIN	0.0029–0.0032	2
GTP	0.0044–0.01	2

Catalyzed reactions (Rhea), 1 shown:

• L-glutaminyl-[protein] + L-lysyl-[protein] = [protein]-L-lysyl-N(6)-5-L-glutamyl-[protein] + NH4(+) (RHEA:54816)

UniProt features (18 total): sequence variant 9, binding site 4, active site 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P49221-F1	92.09	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 268; 327; 350

Ligand- & substrate-binding residues (4): 390; 392; 442; 447

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 62 (showing top): GOBP_PEPTIDE_CROSS_LINKING, OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP, AML_Q6, OCT1_03, MODULE_88, AACTTT_UNKNOWN, MODULE_95, YNGTTNNNATT_UNKNOWN, MODULE_55, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_AMINOACYLTRANSFERASE_ACTIVITY, GSE13762_CTRL_VS_125_VITAMIND_DAY12_DC_DN, MODULE_49, RATTENBACHER_BOUND_BY_CELF1, GOMF_PROTEIN_GLUTAMINE_GAMMA_GLUTAMYLTRANSFERASE_ACTIVITY

GO Biological Process (1): peptide cross-linking (GO:0018149)

GO Molecular Function (4): protein-glutamine gamma-glutamyltransferase activity (GO:0003810), metal ion binding (GO:0046872), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (4): cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein modification process	1
aminoacyltransferase activity	1
catalytic activity, acting on a protein	1
cation binding	1
catalytic activity	1
transferase activity	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
external encapsulating structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

790 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TGM4	ACP3	P15309	882
TGM4	KLK2	P20151	842
TGM4	MSMB	P08118	836
TGM4	KLKB1	P03952	826
TGM4	KLK3	P07288	804
TGM4	STEAP2	Q8NFT2	720
TGM4	SEMG1	P04279	691
TGM4	PATE4	P0C8F1	678
TGM4	GBA1	P04062	669
TGM4	STEAP4	Q687X5	649
TGM4	SYT7	O43581	634
TGM4	PRM2	P04554	597
TGM4	SEMG2	Q02383	570
TGM4	KCNRG	Q8N5I3	514
TGM4	PDILT	Q8N807	512

IntAct

8 interactions, top by confidence:

A	B	Type	Score
TGM4	DDHD2	psi-mi:“MI:0914”(association)	0.530
IGHA1	PLG	psi-mi:“MI:0914”(association)	0.350
IGHG1	PDPK1	psi-mi:“MI:0914”(association)	0.350
ZNF418	ZNF195	psi-mi:“MI:0914”(association)	0.350
DHH	MANBA	psi-mi:“MI:0914”(association)	0.350
RDH11	FN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): GAB2 (Affinity Capture-MS), DDHD2 (Affinity Capture-MS), TGM4 (Affinity Capture-MS), TBC1D14 (Affinity Capture-MS), GAB2 (Affinity Capture-MS), DDHD2 (Affinity Capture-MS), TGM4 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), TGM4 (Affinity Capture-MS), TGM4 (Affinity Capture-MS)

ESM2 similar proteins: A0A140LIF8, A0A2P1BRP3, A0A2P1BRQ0, A0ZSK3, A0ZSK4, A1L314, A8MT19, A8MVJ9, C6FG12, E7F9T0, O81025, P27473, P49221, P58069, Q0GUM3, Q1LYL8, Q1MT80, Q2EMV9, Q3T9E4, Q3UW68, Q4ADG6, Q4ADG7, Q53G44, Q5K651, Q5U311, Q60462, Q60766, Q62293, Q63713, Q66S13, Q66S21, Q66S25, Q69Z37, Q6AYC2, Q84WJ0, Q8BV66, Q8BWR8, Q8CBA2, Q8IVG5, Q8N8V2

Diamond homologs: A6QP57, D4A5U3, O08619, O43548, O46510, O95932, P00488, P08587, P16452, P21980, P21981, P22735, P22758, P23606, P49221, P51176, P52181, P52183, Q01841, Q05187, Q08188, Q08189, Q8BH61, Q8BZH1, Q96PF1, Q99041, Q9D7I9, Q9GLK0, Q9JLF6, Q9WVJ6, P49222, P12260

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

109 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	93
Likely benign	5
Benign	4

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1184858	NM_003241.4(TGM4):c.806G>A (p.Trp269Ter)	Likely pathogenic

SpliceAI

2602 predictions. Top by Δscore:

Variant	Effect	Δscore
3:44874696:AGG:A	donor_loss	1.0000
3:44874698:G:GA	donor_loss	1.0000
3:44885303:A:AG	acceptor_gain	1.0000
3:44885303:ACAT:A	acceptor_gain	1.0000
3:44885305:A:AG	acceptor_gain	1.0000
3:44885305:AT:A	acceptor_gain	1.0000
3:44885305:ATGT:A	acceptor_gain	1.0000
3:44885306:T:G	acceptor_gain	1.0000
3:44885306:T:TA	acceptor_gain	1.0000
3:44885308:T:TA	acceptor_gain	1.0000
3:44887792:AGAGG:A	donor_loss	1.0000
3:44887793:GAG:G	donor_gain	1.0000
3:44887793:GAGGT:G	donor_loss	1.0000
3:44887796:G:T	donor_loss	1.0000
3:44887797:T:G	donor_loss	1.0000
3:44896707:A:AG	acceptor_gain	1.0000
3:44896708:G:GG	acceptor_gain	1.0000
3:44901910:G:GG	donor_gain	1.0000
3:44907180:A:G	donor_gain	1.0000
3:44910956:A:AG	acceptor_gain	1.0000
3:44910957:G:GT	acceptor_gain	1.0000
3:44910957:GT:G	acceptor_gain	1.0000
3:44911086:G:GT	donor_gain	1.0000
3:44911124:AGAGG:A	donor_loss	1.0000
3:44911125:GAG:G	donor_gain	1.0000
3:44911125:GAGGT:G	donor_loss	1.0000
3:44911128:G:GA	donor_loss	1.0000
3:44911129:T:G	donor_loss	1.0000
3:44911269:GTT:G	acceptor_gain	1.0000
3:44874698:G:GG	donor_gain	0.9900

AlphaMissense

4539 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:44903888:T:C	F326L	0.995
3:44903890:C:A	F326L	0.995
3:44903890:C:G	F326L	0.995
3:44901834:T:C	F292L	0.992
3:44901836:C:A	F292L	0.992
3:44901836:C:G	F292L	0.992
3:44890621:A:C	S107R	0.991
3:44890623:T:A	S107R	0.991
3:44890623:T:G	S107R	0.991
3:44901611:A:C	S249R	0.991
3:44901613:T:A	S249R	0.991
3:44901613:T:G	S249R	0.991
3:44890616:T:A	V105D	0.990
3:44907137:A:C	S422R	0.989
3:44907139:C:A	S422R	0.989
3:44907139:C:G	S422R	0.989
3:44907190:G:C	K439N	0.989
3:44907190:G:T	K439N	0.989
3:44893579:G:C	D145H	0.986
3:44893681:T:A	W179R	0.986
3:44893681:T:C	W179R	0.986
3:44901659:T:C	F265L	0.986
3:44901661:T:A	F265L	0.986
3:44901661:T:G	F265L	0.986
3:44890719:C:A	N139K	0.983
3:44890719:C:G	N139K	0.983
3:44901602:T:A	W246R	0.983
3:44901602:T:C	W246R	0.983
3:44901930:T:A	W324R	0.983
3:44901930:T:C	W324R	0.983

dbSNP variants (sampled 300 via entrez): RS1000010685 (3:44901274 T>C), RS1000241473 (3:44879268 T>C), RS1000287450 (3:44895596 G>A), RS1000295817 (3:44891539 A>G), RS1000541892 (3:44877439 C>G), RS1000575454 (3:44895881 G>A), RS1000584243 (3:44880240 G>A), RS1000652271 (3:44912827 A>C), RS1000728206 (3:44887043 G>A), RS1000759376 (3:44877659 A>C), RS1001002211 (3:44896894 A>ACTGTAAGCT), RS1001047600 (3:44874089 C>G), RS1001085733 (3:44905901 A>G), RS1001266374 (3:44905525 C>T), RS1001288134 (3:44888177 T>C)

Disease associations

OMIM: gene MIM:600585 | disease phenotypes: MIM:190300

GenCC curated gene-disease

Mondo (1): essential tremor (MONDO:0003233)

Orphanet (1): NON RARE IN EUROPE: Hereditary essential tremor (Orphanet:862)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST002481_7	Acne (severe)	3.000000e-06
GCST007130_1	Cerebrospinal fluid t-tau:AB1-42 ratio	5.000000e-09
GCST007666_9	Depressive symptom improvement	2.000000e-06
GCST008103_52	Bipolar disorder	3.000000e-07
GCST009936_4	Venous thromboembolism	8.000000e-06
GCST011541_6	Tinnitus	3.000000e-07
GCST90000048_1	Age at first birth	1.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007708	t-tau:beta-amyloid 1-42 ratio measurement
EFO:0007006	depressive symptom measurement
EFO:0009101	age at first birth measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D020329	Essential Tremor	C10.228.662.350

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	3
aristolochic acid I	increases expression	1
apocarotenal	increases expression	1
bisphenol A	affects cotreatment, increases methylation	1
benzo(e)pyrene	increases methylation	1
JP8 aviation fuel	increases expression	1
(+)-JQ1 compound	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Benzo(a)pyrene	increases methylation	1
Calcitriol	decreases expression, affects cotreatment	1
Drugs, Chinese Herbal	increases expression	1
Methapyrilene	increases methylation	1
Naphthoquinones	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Testosterone	decreases expression, affects cotreatment	1
Tretinoin	affects expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases expression	1
beta Carotene	increases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

235 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00439699	PHASE4	COMPLETED	A Pilot Clinical Trial Of Memantine for Essential Tremor
NCT00584376	PHASE4	COMPLETED	Pregabalin (Lyrica) for the Treatment of Essential Tremor
NCT00998660	PHASE4	COMPLETED	RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
NCT02111369	PHASE4	COMPLETED	Propranolol and Botulinum Toxin for Essential Vocal Tremor
NCT02495883	PHASE4	COMPLETED	Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response
NCT00018564	PHASE3	COMPLETED	Novel Therapies for Essential Tremor
NCT00236496	PHASE3	COMPLETED	A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
NCT01441284	PHASE3	WITHDRAWN	Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
NCT04193527	PHASE3	COMPLETED	A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
NCT04265209	PHASE3	COMPLETED	[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson’s Diseases and Essential Tremor
NCT06087276	PHASE3	ENROLLING_BY_INVITATION	Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
NCT00080366	PHASE2	COMPLETED	Octanol to Treat Essential Tremor
NCT00102596	PHASE2	COMPLETED	Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
NCT00223743	PHASE2	COMPLETED	A Safety/Efficacy Trial of Zonisamide for Essential Tremor
NCT00321087	PHASE2	TERMINATED	A Study of T2000 in Essential Tremor
NCT00598078	PHASE2	COMPLETED	Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
NCT00655278	PHASE2	TERMINATED	T2000 in Essential Tremor - Open Label Continuation
NCT01332695	PHASE2	COMPLETED	A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
NCT02277106	PHASE2	COMPLETED	Evaluate SAGE-547 in Participants With Essential Tremor
NCT02551848	PHASE2	UNKNOWN	Kinematic-based BoNT-A Injections for Bilateral ET
NCT02668146	PHASE2	UNKNOWN	An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor
NCT02978781	PHASE2	COMPLETED	A Study to Evaluate SAGE-217 in Participants With Essential Tremor
NCT03101241	PHASE2	COMPLETED	A Phase 2 RCT Study of CX-8998 for Essential Tremor
NCT03688685	PHASE2	COMPLETED	A Clinical Study to Evaluate CAD-1883 in Essential Tremor
NCT03780426	PHASE2	COMPLETED	tSMS in Essential Tremor
NCT04305275	PHASE2	COMPLETED	A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
NCT04727658	PHASE2	TERMINATED	Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL)
NCT04880616	PHASE2	COMPLETED	Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
NCT05021978	PHASE2	COMPLETED	A Clinical Trial of PRAX-944 in Participants With Essential Tremor
NCT05021991	PHASE2	COMPLETED	A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
NCT05122650	PHASE2	COMPLETED	A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
NCT05173012	PHASE2	COMPLETED	Study to Evaluate SAGE-324 in Participants With Essential Tremor
NCT05387642	PHASE2	WITHDRAWN	A Clinical Trial of PRAX-114 in Participants With Essential Tremor
NCT06312800	PHASE2	WITHDRAWN	Acamprosate and Methazolamide for Essential Tremor
NCT06821906	PHASE2	RECRUITING	Stereotactic Radiosurgery in the Treatment of Essential Tremor
NCT07074002	PHASE2	RECRUITING	Proof of Concept Study on BP1.4979 Effect on Essential Tremor
NCT07103265	PHASE2	NOT_YET_RECRUITING	Developing a New LIFU Neuromodulation Method to Suppress Tremor
NCT00001986	PHASE1	COMPLETED	1-Octanol to Treat Essential Tremor
NCT00016679	PHASE1	COMPLETED	1-Octanol to Treat Essential Tremor
NCT01304758	PHASE1	COMPLETED	ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor